Navigation Links
BioMarin Receives Orphan Drug Designation from the FDA for BMN-701 for the Treatment of Pompe Disease
Date:8/30/2010

NOVATO, Calif., Aug. 30 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that it has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for BMN-701, a novel fusion of insulin-like growth factor 2 and alpha glucosidase (IGF2-GAA) in development for the treatment of Pompe disease.  An investigational new drug application (IND) for BMN-701 has been submitted, investigational material has been manufactured and a Phase I/II study is expected to start in the first quarter of 2011.

"Receiving orphan drug designation from the FDA for BMN-701 is a significant milestone for our Pompe program.  As part of their assessment for designation, the FDA determined that BMN-701 is sufficiently different from alglusidase alfa (Myozyme/Lumizyme) to allow for a unique orphan designation.  For this reason, clinical superiority over alglusidase alfa will not be necessary to secure orphan exclusivity for BMN-701," said Jean-Jacques Bienaime, Chief Executive Officer of BioMarin.  "This emphasizes our mission of developing innovative, products for orphan diseases with an unmet medical need.  We believe BMN-701 has the potential to possibly deliver more enzyme to lysosomes compared to traditional mannose-6-phosphate targeted approaches using the recently acquired GILT technology."  

About Pompe DiseasePompe disease, a lysosomal storage disorder, is a progressive degenerative disease of the heart muscle, diaphragm and skeletal muscle.  It is caused by a deficiency in the lysosomal enzyme acid alpha glucosidase which leads to the accumulation of glycogen in myocyte lysosomes and results in cell death.  The incidence is one in 40,000 births.  There are two main forms of Pompe disease: adult onset with an incidence of one in 57,000 births and infantile onset with an incidence of one in
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
2. BioMarin Announces FDA Approval for Kuvan
3. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
4. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
5. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
6. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
7. BioMarin Acquires Huxley Pharmaceuticals, Inc.
8. BioMarin to Present at the Oppenheimer Healthcare Conference
9. BioMarin Announces Third Quarter 2009 Financial Results
10. BioMarin to Acquire LEAD Therapeutics
11. BioMarin to Present at the Credit Suisse Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... Mass. , July 28, 2015  Alere Inc. ... diagnostics, today announced that it will release its financial ... The Company will host a conference call beginning at ... discuss these results and provide business updates. ... the Investor Relations section of Alere,s website, or accessed ...
(Date:7/28/2015)... 28, 2015  Roche (SIX: RO, ROG; OTCQX: ... for Clinical Chemistry (AACC) 2015 Clinical Lab Expo ... and a unique educational initiative that demonstrates how ... value of the laboratory. The new ... empower laboratories and the people within them through ...
(Date:7/28/2015)... 28, 2015  Cepheid (Nasdaq: CPHD ) ... portable clinical molecular diagnostic system designed to meet ... At just 9 inches tall, and weighing just ... same high quality PCR-based Xpert® cartridges as Cepheid,s ... clinical molecular diagnostic tests to be performed in ...
Breaking Medicine Technology:Alere to Report Second Quarter 2015 Financial Results on August 4, 2015 2Roche introduces LabLeaders educational initiative to help redefine the value of the laboratory at AACC 2015 Clinical Lab Expo 2Roche introduces LabLeaders educational initiative to help redefine the value of the laboratory at AACC 2015 Clinical Lab Expo 3Roche introduces LabLeaders educational initiative to help redefine the value of the laboratory at AACC 2015 Clinical Lab Expo 4World's First "Go-Anywhere" Molecular Diagnostic System Unveiled at AACC 2World's First "Go-Anywhere" Molecular Diagnostic System Unveiled at AACC 3World's First "Go-Anywhere" Molecular Diagnostic System Unveiled at AACC 4
... (NYSE: ZMH ; SIX: ZMH), a global leader in ... Zimmer Natural Nail Cephalomedullary Nail in the United ... Natural Nail system features an innovative design focused ... Natural Nail Cephalomedullary Nail is designed to help address ...
... Dan Onorato, along with physicians, nurses, patients, political leaders ... in a free public event on Wednesday, October 20, ... have on the health care industry, cardiovascular care and ... Means for You," will take place at the Magovern ...
Cached Medicine Technology:Zimmer® Announces 1000th Implantation of Its Natural Nail™ Cephalomedullary Nail 2Zimmer® Announces 1000th Implantation of Its Natural Nail™ Cephalomedullary Nail 3Health Care and Community Leaders Discuss the Impact of Health Care Reform in Pennsylvania 2Health Care and Community Leaders Discuss the Impact of Health Care Reform in Pennsylvania 3Health Care and Community Leaders Discuss the Impact of Health Care Reform in Pennsylvania 4
(Date:7/28/2015)... , ... July 28, 2015 , ... ... of Directors has authorized the Company, from time to time and depending on ... value of up to $25 million. Repurchases will be made in open market ...
(Date:7/28/2015)... ... July 28, 2015 , ... ... in shipbreaking workers than they are in the general population. Surviving Mesothelioma has ... it now. , Researchers at Taiwan’s National Health Research Institutes and three ...
(Date:7/28/2015)... ... July 28, 2015 , ... ... include a proprietary, web based clinical knowledge system, called “Referral Guidance.” ... It provides physicians who are anticipating making a subspecialty referral an efficient ...
(Date:7/28/2015)... ... July 28, 2015 , ... Women fear developing Alzheimer's ... is that cancer, heart attack, and stroke are treatable, but there is little an ... do is to take part in a clinical trial, reports the July 2015 ...
(Date:7/28/2015)... ... July 28, 2015 , ... Fertility specialist Dr. Lisa Hasty ... 2015” by Atlanta Magazine. In Atlanta Magazine's annual Top Doctors issue, Dr. Hasty has ... colleagues and peers in the metro area as one of the most respected doctors ...
Breaking Medicine News(10 mins):Health News:Safeguard Scientifics Board of Directors Authorizes up to $25 Million Share Repurchase Program 2Health News:Safeguard Scientifics Board of Directors Authorizes up to $25 Million Share Repurchase Program 3Health News:New Findings Suggest Mesothelioma is Not the Only Cancer Threat for Shipbreakers, According to Surviving Mesothelioma 2Health News:Introducing Care to Care’s New Web Based “Referral Guidance” Program 2Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 2Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 3Health News:Atlanta Fertility Specialist Named Top Doctor in Atlanta Magazine 2Health News:Atlanta Fertility Specialist Named Top Doctor in Atlanta Magazine 3
... in the U.S. are suffering from long-term spinal cord injuries, ... ,One study appearing in the July 12th issue ... right track towards providing evidence that a combination of treatments ... injured patients. The result would be a return of functional ...
... babies born in the United States are screened for ... the March of Dimes and the American Academy of ... of Medical Genetics calling for expanded screening for 29 ... and child health expert Russell Kirby, Ph.D., agrees. “All ...
... sleep and exercise for glowing skin. Precious stones are the ... fad of gem stone facials is fast catching on in ... offering facials that use 'bhasm' (ash) of stones like rubies, ... ,"Bhasm of these stones is used in ayurveda to treat ...
... An intermittent treatment with sulfadoxine-pyrimethamine, a common and cheap ... children //by Rafael Pardo, director of the Fundación BBVA, ... Health of Hospital Clínic de Barcelona. The findings of ... issue of the Journal of Infectious Diseases. ...
... of questions being raised about its autonomy, a high-level expert ... Medical Sciences// (AIIMS) "as immune as possible from authorities". ... which will make AIIMS as immune as possible from authorities," ... the four-member expert committee on AIIMS affairs, told PTI from ...
... likely to have serious heart problems as those who live ... a study published in the Journal of Epidemiology and Community ... of 30 and 69 living in one area of Denmark ... more common in the lifestyles of people who live alone. ...
Cached Medicine News:Health News:Astro Gem Therapy: The Latest Beauty Secret for Glowing Skin 2Health News:Intermittent Treatment Found Effective In Malaria 2Health News:Intermittent Treatment Found Effective In Malaria 3Health News:Intermittent Treatment Found Effective In Malaria 4Health News:Intermittent Treatment Found Effective In Malaria 5
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: